Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TK2 | O00142 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25504633 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL25505398 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL19224119 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL14063727 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL889722 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL25505352 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL12453196 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL12352406 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL12149468 | 1.00 | TK1 (0.69) | TK1POLBTK2 | |
| SCHEMBL655193 | 0.91 | TK1 (0.67) | TK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2023-06-29 | — | — | US | disclosed |
| EP-2157095-A2 | Synthesis of beta-L-2-Deoxy nucleosides | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TK1 37/4885POLB 16/4885TK2 134/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | TK1 37/4885POLB 16/4885TK2 134/4885 |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | PPIP5K2, INPP5B, PTMS | TK1 1705/4885POLB 1692/4885TK2 2122/4885 |
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | NT5C3B, PNP, NME1 | TK1 190/4885POLB 101/4885TK2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.